全球不孕症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計不孕症治療市場將從 2025 年的 43.6 億美元成長到 2034 年的 75.8 億美元，2026 年至 2034 年的複合年成長率為 6.34%。

隨著全球不孕症的上升，全球不孕症治療藥物市場正經歷顯著成長。生活方式的改變、受孕延遲以及生殖健康問題的增加是導致男性和女性不孕症的主要因素。不孕症治療藥物廣泛應用於輔助生殖技術中，以促進排卵並提高懷孕成功率。

生殖醫學的進步和人們對不孕症治療認知的提高正在推動對不孕症藥物的需求。醫療機構提供多種藥物療法，包括荷爾蒙療法和促排卵藥物，作為不孕症治療方案的一部分。此外，不孕症診所的擴張和輔助生殖技術普及程度的提高也促進了市場成長。

展望未來，隨著生殖醫學研究的不斷深入，全球不孕症治療市場預計將持續成長。製藥公司正在研發創新藥物，以提高治療效果並減少副作用。隨著人們對不孕症治療的健康意識不斷提高以及治療服務的不斷擴展，不孕症治療市場預計將保持持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球不孕症治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 促性腺激素分泌
• Aromatase抑制劑
• 選擇性雌激素受體調節（SERMs）
• 多巴胺促效劑
• 其他

第5章：全球不孕症藥物市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 專科藥房和零售藥房
• 網路藥房

第6章：全球不孕症藥物市場：依最終用戶分類

• 市場分析、洞察與預測
• 男性
• 女士

第7章 全球不孕症治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck & Co. Inc
  • Ferring BV
  • Organon Group Of Companies
  • Abbott
  • Novartis AG
  • Bayer AG
  • Pfizer Inc
  • Mankind Pharma
  • Teva Pharmaceutical Industries LTD
  • Sanofi

The Infertility Drugs Market size is expected to reach USD 7.58 Billion in 2034 from USD 4.36 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.

The Global Infertility Drugs Market is witnessing significant growth as infertility rates continue to rise worldwide. Lifestyle changes, delayed pregnancies, and increasing prevalence of reproductive health disorders are major factors contributing to infertility among both men and women. Infertility drugs are widely used in assisted reproductive treatments to stimulate ovulation and improve the chances of successful conception.

Advancements in reproductive medicine and increasing awareness about fertility treatments are driving demand for infertility drugs. Healthcare providers are offering a wide range of pharmaceutical treatments as part of fertility therapy programs, including hormone therapies and ovulation induction medications. In addition, the expansion of fertility clinics and improved access to assisted reproductive technologies are supporting market growth.

Looking ahead, the Global Infertility Drugs Market is expected to grow as research in reproductive medicine continues to advance. Pharmaceutical companies are developing innovative drug formulations that improve treatment outcomes and reduce side effects. With increasing awareness about fertility health and expanding fertility treatment services, the market for infertility drugs is projected to experience sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Gonadotropins
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Dopamine Agonists
• Others

By Distribution Channel

• Hospital Pharmacy
• Specialty & Retail Pharmacy
• Online Pharmacy

By End-user

• Men
• Women

COMPANIES PROFILED

• Merck Co Inc, Ferring BV, Organon Group of Companies, Abbott, Novartis AG, Bayer AG, Pfizer Inc, Mankind Pharma, Teva Pharmaceutical Industries LTD, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFERTILITY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Gonadotropins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aromatase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Selective Estrogen Receptor Modulators (SERMs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Dopamine Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INFERTILITY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty & Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INFERTILITY DRUGS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Men Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Women Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INFERTILITY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Distribution Channel
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Distribution Channel
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Distribution Channel
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Distribution Channel
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Distribution Channel
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INFERTILITY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 Ferring B.V
  • 9.2.3 Organon Group Of Companies
  • 9.2.4 Abbott
  • 9.2.5 Novartis AG
  • 9.2.6 Bayer AG
  • 9.2.7 Pfizer Inc
  • 9.2.8 Mankind Pharma
  • 9.2.9 Teva Pharmaceutical Industries LTD
  • 9.2.10 Sanofi